Table 2.
Univariate probabilities of clinical outcomes by Histocheck (DSS) score quartiles of mismatched cases
| Outcomes | Time point | Percent Probability (95% CI) | P-valuea | |||
|---|---|---|---|---|---|---|
| Group 1 DSS 1.04 – 2.84 |
Group 2 DSS >2.84 – 13.75 |
Group 3 DSS >13.75 – 19.39 |
Group 4 DSS >13.39 – 36.62 |
|||
| Acute GVHD II-IV | 100 days | 51 (44–59) | 51 (44–58) | 56 (49–63) | 51 (44–58) | 0.75 |
| Chronic GVHD | 1 year | 39 (32–47) | 34 (27–42) | 35 (28–42) | 38 (31–46) | 0.70 |
| Treatment related mortality | 1 year | 41 (34–48) | 49 (42–56) | 44 (37–52) | 45 (38–52) | 0.48 |
| 3 years | 46 (39–53) | 51 (44–58) | 54 (46–61) | 49 (42–57) | 0.54 | |
| 5 years | 48 (41–56) | 54 (47–61) | 55 (48–62) | 52 (44–59) | 0.59 | |
| Relapse | 1 year | 14 (10–20) | 16 (11–22) | 14 (9–19) | 19 (14–25) | 0.53 |
| 3 years | 18 (13–24) | 21 (16–27) | 17 (12–22) | 25 (19–31) | 0.25 | |
| 5 years | 19 (14–25) | 21 (16–27) | 18 (13–24) | 25 (19–31) | 0.44 | |
| Overall survival | 1 year | 47 (40–54) | 41 (34–48) | 46 (39–53) | 41 (34–49) | 0.50 |
| 3 years | 38 (31–45) | 32 (25–39) | 33 (27–40) | 29 (23–36) | 0.31 | |
| 5 years | 35 (28–43) | 28 (22–35) | 31 (24–38) | 26 (19–33) | 0.26 | |
| Disease free survival | 1 year | 45 (38–52) | 35 (28–42) | 42 (35–49) | 36 (29–43) | 0.16 |
| 3 years | 35 (29–43) | 27 (21–34) | 30 (23–37) | 26 (20–33) | 0.21 | |
| 5 years | 33 (26–40) | 25 (19–31) | 27 (21–34) | 24 (17–31) | 0.28 | |
| Neutrophil engraftment | 28 days | 92 (88–95) | 90 (86–94) | 87 (81–91) | 85 (79–89) | 0.09 |
a
P-values are pointwise